NVAX — NOVAVAX INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1000694 ·
Last close
$7.96
Market Cap
$1.31B
52W High
$13.39
52W Low
$6.20
ADV30
6,970,439
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 68,298,000 | 44,810,000 | -31,281,000 | -31,376,000 | 888,005,000 | 222,455,000 | 1,104,860,000 |
| Jun 2026 | 56,698,000 | 42,452,000 | -54,906,000 | -53,387,000 | 955,575,000 | 191,458,000 | 1,146,282,000 |
| Mar 2026 | 139,514,000 | 108,819,000 | -15,430,000 | -9,491,000 | 1,043,162,000 | 228,363,000 | 1,187,924,000 |
| Dec 2025 | 147,139,000 | 125,035,000 | 15,037,000 | 17,527,000 | 1,176,512,000 | 240,634,000 | 1,304,265,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-36,901,000
Investing CF
$-109,510,000
Financing CF
$74,714,000
CapEx
$-6,124,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.52
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-4,631,026,000
Inventory
$10,006,000
Receivables
$18,739,000
ST Investments
$527,882,000
EBIT TTM
$-223,419,000
Pretax Income TTM
$-245,315,000
Interest Exp TTM
$21,896,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$411,648,992
EBITDA
$-55,594,000
Free Cash Flow
$11,756,062
Enterprise Value
$1,451,697,152
Total Cash
$622,363,008
Total Debt
$295,263,008
Shares Out
165,009,009
Trailing EPS
$-0.52
Book Value
$-1.31
ROE
—
ROA
-4.2%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,123,479,000 | 550,640,000 | 440,302,000 | 1,176,512,000 | 1,304,265,000 | -127,753,000 | -244,635,000 |
| Dec 2024 | 682,162,000 | -248,931,000 | -187,499,000 | 1,560,418,000 | 2,184,259,000 | -623,841,000 | -87,263,000 |
| Dec 2023 | 556,382,000 | -566,511,000 | -545,062,000 | 1,797,490,000 | 2,514,417,000 | -716,927,000 | -713,967,000 |
| Dec 2022 | 1,598,951,000 | -644,736,000 | -657,939,000 | 2,258,679,000 | 2,892,757,000 | -634,078,000 | -415,937,000 |
TTM Snapshot
Revenues TTM
$413,796,000
NetIncome TTM
$-247,730,000
OpCashFlow TTM
—
Assets (Latest)
$955,575,000
Forward EPS
$-0.51
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $8.00 · spot: $7.96 · call volume: 3,364 · put volume: 72
Expected Move to 2027-04-16:
±$3.02
(37.94%) —
implied range
$4.94 –
$10.98
· ATM straddle on $8.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TSHA | Taysha Gene Therapies, Inc. | $1.30B | $4.00 | — |
| IMCR | Immunocore Holdings plc | $1.43B | $27.81 | — |
| MEOBF | MESOBLAST LTD | $1.48B | $1.14 | — |
| VOR | Vor Biopharma Inc. | $1.12B | $18.18 | — |
| MESO | MESOBLAST LTD | $1.55B | $11.91 | — |
News headlines (Yahoo Finance, 1h cache)
Novavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine Trial
2026-11-17 21:12 · Yahoo
Novavax to Participate in Jefferies London Healthcare Conference
2026-11-11 22:00 · Yahoo
NVAX Q3 2026 deep dive: Sanofi milestone and cost controls shape outlook
2026-11-10 13:01 · Yahoo
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
2026-11-10 13:00 · Yahoo
Novavax (NVAX) stock trades up, here is why
2026-11-10 06:45 · Yahoo
Novavax (NVAX) Looks Cheap After Sanofi Milestone And Stronger Q3 Results
2026-11-07 16:10 · Yahoo
Novavax Q3 Earnings Call Highlights
2026-11-06 10:14 · Yahoo
Novavax Inc (NVAX) (Q3 2026) Earnings Call Highlights: Sanofi Milestone Lifts Revenue Outlook ...
2026-11-06 01:15 · Yahoo
Novavax (NVAX) reports earnings tomorrow: what to expect
2026-11-05 23:41 · Yahoo
Novavax (NVAX) Q3 2026 Earnings Call Transcript
2026-11-05 20:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.